Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Austin Health.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Austin Health
ClinicalTrials.gov Identifier:
NCT00973713
First received: September 8, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted

September 8, 2009
September 8, 2009
September 2009
September 2011   (final data collection date for primary outcome measure)
Tumour control [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
  • Overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Toxicity [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol
Phase II Study of RAD001 in Advanced Cholangiocarcinoma

This is a clinical trial investigating the effectiveness and safety of the study drug RAD001 in patients with advanced (metastatic) cholangiocarcinoma. Palliative chemotherapy provides some benefit to this group of patients. However, chemotherapy treatment only shows low rates of radiological response and short times to tumour progression. Therefore, further treatment options are urgently required.

In laboratory studies, RAD001 has been shown to interrupt the signals that cancer cells use to grow, spread and form new blood vessels (angiogenesis). RAD001 has been approved for the treatment of kidney cancer. It has also been approved for use in Australia for the treatment of patients with kidney and liver transplants, and has been used in thousands of patients worldwide for this indication. Preliminary studies suggest that RAD001 may have activity in a range of other cancers. This study will evaluate the activity of RAD001 in advanced cholangiocarcinoma.

27 patients from approximately four hospitals in Australia will participate in this trial, with approximately 15 patients being enrolled at Austin Health. All participants will receive the same treatment (RAD001 10mg/d given orally).

After screening for eligibility, participants will receive RAD001 10mg/d until tumour progression.

Participants will undergo regular CT scans (every 6 weeks during treatment) to evaluate the effectiveness of treatment. Providing they are tolerating treatment satisfactorily, they may receive study treatment until progression of disease.

Blood samples will be taken during the screening phase and every 3 weeks during the treatment phase of the trial. Participants will be followed-up every 3 months to find out about survival status, new chemotherapy or biological treatment and the outcome of any ongoing adverse events.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Cholangiocarcinoma
Drug: RAD001
10mg/d
Other Name: Everolimus
Experimental: RAD001 10mg/d
Intervention: Drug: RAD001
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
27
March 2012
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Histologically/cytologically confirmed adenocarcinoma of gall bladder, intra or extra-hepatic biliary tract
  2. Metastatic or locally advanced (unresectable) disease
  3. Adequate organ function; creatinine<1.5xULN, BR<1.5xULN Neut>1.5, Pts>100
  4. WHO Performance status 0-2
  5. No prior chemotherapy for advanced Cholangiocarcinoma (Prior adjuvant chemotherapy is accepted)
  6. Measurable or non-measurable disease
  7. Informed consent for study participation and donation of tumour tissue for evaluation of relevant translational endpoints

Exclusion Criteria:

  1. Cytotoxic chemotherapy or immunotherapy within 4 weeks prior to enrolment
  2. Prior therapy with mTOR inhibitors (sirolimus, temsirolimus, everolimus)
  3. Known intolerance or hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus)
  4. Uncontrolled diabetes mellitus or hyperlipidaemia
  5. Patients who have any severe and/or uncontrolled medical conditions
  6. Active or uncontrolled severe infection
  7. Cirrhosis, chronic active hepatitis or chronic persistent hepatitis
  8. Severely impaired lung function
  9. Patients with a known history of HIV seropositivity
  10. Patients who have a history of another primary malignancy (Exceptions include non-melanoma skin cancer, carcinoma in situ of uterine cervix, or any other cancer treated with curative intent without evidence of relapse for more than 2 years)
  11. Female patients who are pregnant or nursing (lactating), or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes
Both
18 Years and older
No
Contact: Niall Tebbutt, FRACP +61394965763 niall.tebbutt@ludwig.edu.au
Contact: Effie Roiniotis, RN +61394963576 effie.roiniotis@ludwig.edu.au
Australia
 
NCT00973713
H2009/3522
Yes
Niall Tebbutt, Austin Health
Austin Health
Not Provided
Not Provided
Austin Health
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP